Title: Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus
genotype 2: a systematic review and meta-analysis
Version: 1 Date: 15 Jun 2024
Reviewer's report:
Summary of Study on DAAs Efficacy for GT2 SVR
This study is a significant effort to compile various studies evaluating the efficacy of Direct-
Acting Antivirals (DAAs) on genotype 2 (GT2) sustained virologic response (SVR). It is well
written with very few typos.
Methods
The methods used in the study are generally appropriate and acceptable. However, there are a
few important considerations:
Duplicate Studies:
It appears that some duplicate studies, indicated by the same author ID, are included in the meta-
analysis. This could skew the results.
Recommendation: Remove duplicate studies to ensure accurate results.
Hierarchical Model Analysis:
An exploratory hierarchical model analysis should be performed if it has not been done already.
This analysis can provide more robust results by accounting for the variability between different
study levels.
Separation of Patient Groups:
The analysis should separate patients based on their prior exposure to DAAs and/or injectables/
ribavirin combinations. Specifically:
Treatment-naive patients
Treatment-experienced patients
Combined groups
This distinction can provide more precise insights into the efficacy of DAAs for different patient
groups.
Strong consideration of Network Meta-Analysis:
The authors should consider using Network Meta-Analysis (NMA) instead of traditional
meta-analysis.NMA can compare multiple treatments simultaneously and provide a more
comprehensive assessment of their relative effectiveness.
For instance, in the context of evaluating the efficacy of Direct-Acting Antivirals (DAAs)
for Hepatitis C Virus (HCV) genotype 2 (GT2) SVR, NMA can compare multiple DAA
regimens (e.g., SOF+VEL, GLE+PIB, SOF+VEL+VOX) simultaneously. Even if some of these
regimens have not been directly compared in trials, NMA can use data from studies where these
regimens were compared against a common control to estimate their relative effectiveness. This
comprehensive approach provides a clearer picture of which regimen is most effective for GT2
SVR, guiding treatment decisions and optimizing patient outcomes.
Discussion
The discussion section will depend significantly on the un-skewed results obtained after
addressing the above issues and/or the use of more advanced methods like Network Meta-
Analysis. The authors should emphasize the clinical significance of their findings to all
stakeholders, highlighting how these results can impact treatment decisions and patient
outcomes.
Title: Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus
genotype 2: a systematic review and meta-analysis
Version: 1 Date: 15 Jun 2024
Reviewer's report:
Summary of Study on DAAs Efficacy for GT2 SVR
This study is a significant effort to compile various studies evaluating the efficacy of Direct-
Acting Antivirals (DAAs) on genotype 2 (GT2) sustained virologic response (SVR). It is well
written with very few typos.
Methods
The methods used in the study are generally appropriate and acceptable. However, there are a
few important considerations:
Duplicate Studies:
It appears that some duplicate studies, indicated by the same author ID, are included in the meta-
analysis. This could skew the results.
Recommendation: Remove duplicate studies to ensure accurate results.
Hierarchical Model Analysis:
An exploratory hierarchical model analysis should be performed if it has not been done already.
This analysis can provide more robust results by accounting for the variability between different
study levels.
Separation of Patient Groups:
The analysis should separate patients based on their prior exposure to DAAs and/or injectables/
ribavirin combinations. Specifically:
Treatment-naive patients
Treatment-experienced patients
Combined groups
This distinction can provide more precise insights into the efficacy of DAAs for different patient
groups.
Strong consideration of Network Meta-Analysis:
The authors should consider using Network Meta-Analysis (NMA) instead of traditional
meta-analysis.NMA can compare multiple treatments simultaneously and provide a more
comprehensive assessment of their relative effectiveness.
For instance, in the context of evaluating the efficacy of Direct-Acting Antivirals (DAAs)
for Hepatitis C Virus (HCV) genotype 2 (GT2) SVR, NMA can compare multiple DAA
regimens (e.g., SOF+VEL, GLE+PIB, SOF+VEL+VOX) simultaneously. Even if some of these
regimens have not been directly compared in trials, NMA can use data from studies where these
regimens were compared against a common control to estimate their relative effectiveness. This
comprehensive approach provides a clearer picture of which regimen is most effective for GT2
SVR, guiding treatment decisions and optimizing patient outcomes.
Discussion
The discussion section will depend significantly on the un-skewed results obtained after
addressing the above issues and/or the use of more advanced methods like Network Meta-
Analysis. The authors should emphasize the clinical significance of their findings to all
stakeholders, highlighting how these results can impact treatment decisions and patient
outcomes.
Please review this paper.
user
Title: Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus
genotype 2: a systematic review and meta-analysis
Version: 1 Date: 15 Jun 2024
Reviewer's report:
Summary of Study on DAAs Efficacy for GT2 SVR
This study is a significant effort to compile various studies evaluating the efficacy of Direct-
Acting Antivirals (DAAs) on genotype 2 (GT2) sustained virologic response (SVR). It is well
written with very few typos.
Methods
The methods used in the study are generally appropriate and acceptable. However, there are a
few important considerations:
Duplicate Studies:
It appears that some duplicate studies, indicated by the same author ID, are included in the meta-
analysis. This could skew the results.
Recommendation: Remove duplicate studies to ensure accurate results.
Hierarchical Model Analysis:
An exploratory hierarchical model analysis should be performed if it has not been done already.
This analysis can provide more robust results by accounting for the variability between different
study levels.
Separation of Patient Groups:
The analysis should separate patients based on their prior exposure to DAAs and/or injectables/
ribavirin combinations. Specifically:
Treatment-naive patients
Treatment-experienced patients
Combined groups
This distinction can provide more precise insights into the efficacy of DAAs for different patient
groups.
Strong consideration of Network Meta-Analysis:
The authors should consider using Network Meta-Analysis (NMA) instead of traditional
meta-analysis.NMA can compare multiple treatments simultaneously and provide a more
comprehensive assessment of their relative effectiveness.
For instance, in the context of evaluating the efficacy of Direct-Acting Antivirals (DAAs)
for Hepatitis C Virus (HCV) genotype 2 (GT2) SVR, NMA can compare multiple DAA
regimens (e.g., SOF+VEL, GLE+PIB, SOF+VEL+VOX) simultaneously. Even if some of these
regimens have not been directly compared in trials, NMA can use data from studies where these
regimens were compared against a common control to estimate their relative effectiveness. This
comprehensive approach provides a clearer picture of which regimen is most effective for GT2
SVR, guiding treatment decisions and optimizing patient outcomes.
Discussion
The discussion section will depend significantly on the un-skewed results obtained after
addressing the above issues and/or the use of more advanced methods like Network Meta-
Analysis. The authors should emphasize the clinical significance of their findings to all
stakeholders, highlighting how these results can impact treatment decisions and patient
outcomes.
assistant